Sorrento Therapeutics Inc (SRNE)

[dia76ca]

The Oct.12 presentation on NSCLC and ABIVERTINIB is interesting although I found some hard to understand but if I got it right ABI seems to have a lower ORR rate than OSI (although it is 57%!) but it produces a 5% CR rate compared to none! And it has a superior 28+ month OS rate! And it is a far less costly drug which is important to both health care systems and patients!
It looks like the first approvals could come in Mexico and Latin America followed by China and Europe with the US trailing although the cost issue may hasten worldwide approvals. And we must not think that these other markets are insignificant. Latin America(600 million), China(1.5 billion) and Europe(700 million) are all larger than the US(333 million).
https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI%3A4%3BF%3AQS%2110100&ShowUUID=1DF26B36-EA1A-4E30-8FC3-7FFC6EF6026B